{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.26","value":"6.3"},{"groupId":"OG001","spread":"16.36","value":"7.5"}]}],"title":"SBP, Week 2; n=139, 147"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.65","value":"-0.4"},{"groupId":"OG001","spread":"17.21","value":"7.5"}]}],"title":"SBP, Week 6; n=109, 134"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.43","value":"4.5"},{"groupId":"OG001","spread":"20.45","value":"4.7"}]}],"title":"SBP, Week 10; n=61, 64"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.91","value":"6.5"},{"groupId":"OG001","spread":"10.49","value":"6.5"}]}],"title":"DBP, Week 2; n=139, 147"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.48","value":"-0.4"},{"groupId":"OG001","spread":"10.87","value":"6.9"}]}],"title":"DBP, Week 6; n=109, 134"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.69","value":"3.1"},{"groupId":"OG001","spread":"11.44","value":"5.6"}]}],"title":"DBP, Week 10; n=61, 64"}],"denoms":[{"counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"147"}],"units":"Participants"}],"description":"When the heart beats, it contracts and pushes blood through the arteries to the rest of body. This force creates pressure on the arteries called SBP. DBP is the pressure in the arteries when the heart rests between beats. Normal levels: SBP (120 mmHg or less); DBP (80 mmHg or less). Mean change from BL for each assessment week was calculated as the average change from period BL at the specified visits (combining data across P 1 and 2 for Weeks 2 and 6). Study weeks are approximate; participants could have crossed over from P 1 to P 2 at earlier time points than specified in the protocol.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 4 overencapsulated capsules of sunitinib (either in Period 1 or Period 2), each containing 12.5 mg of sunitinib, OD orally for 4 weeks, followed by 2 weeks off treatment (matching placebo capsules to maintain blind), followed by 50 mg (4 x 12.5 mg) OD orally for 4 weeks. Study drug was taken orally OD without food at least one hour before or two hours after a meal. The capsules were swallowed whole and not crushed or broken. The time of day the study drug was taken remained relatively constant.","id":"OG000","title":"Sunitinib"},{"description":"Participants received 4 overencapsulated tablets of pazopanib (either in Period 1 or Period 2), each containing 200 mg of pazopanib, OD orally for 10 weeks. Study drug was taken orally OD without food at least one hour before or two hours after a meal. The capsules were swallowed whole and not crushed or broken. The time of day the study drug was taken remained relatively constant.","id":"OG001","title":"Pazopanib"}],"paramType":"MEAN","populationDescription":"Safety-Randomized Study Population. All participants who received sunitinib or pazopanib either during Period 1 or Period 2 were counted in both treatment groups (sunitinib and pazopanib). Only those participants contributing data at the indicated time points were evaluated.","reportingStatus":"POSTED","timeFrame":"Baseline of Period (P) 1 (Screening); Period 1 Weeks 2 and 6 (Study Weeks 2 and 6); Baseline of Period 2 (Washout=Study Week 12); Period 2 Weeks 2, 6, and 10 (Study Weeks 14, 18, and 22)","title":"Change From Baseline (BL) in Systolic Blood Pressure (SBP) and Diastolic BP (DBP)","type":"SECONDARY","unitOfMeasure":"Millimeters of mercury (mmHg)"}